Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head and neck cancer, after revealing promising phase 3 trial results.
Novartis has announced it would not raise drug prices in the US this year, while Merck & Co announced huge cuts in the price of its hepatitis drug following pressure from president Trum
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl